Department of Pharmacy, University of Colorado Hospital, Aurora, Colorado, USA.
Anticancer Drugs. 2013 Jan;24(1):1-13. doi: 10.1097/CAD.0b013e32835a5ca3.
High-dose interleukin-2, administered as a single agent or in combination with antineoplastic agents, known as biochemotherapy, holds the promise of durable remissions for patients with metastatic renal cell carcinoma and metastatic melanoma. The toxicities arising from high-dose interleukin-2-based therapies affect every organ system, causing significant acute morbidity. Administration of high-dose interleukin-2-based therapies requires specialized care and knowledge because of the severity and uniqueness of toxicities compared with the toxicities encountered with other forms of anticancer therapy. However, the toxicities of high-dose interleukin-2-based therapies are predictable and manageable by vigilant monitoring and appropriate supportive care protocols. To maximize outcomes, both acute and delayed toxicities require vigilant monitoring and adroit symptom management. This review details the pathophysiology, monitoring parameters, and management strategies for patients receiving high-dose interleukin-2-based therapy, with a focus on new and important management principles.
高剂量白细胞介素-2 作为单一药物或与抗肿瘤药物联合使用，即生物化疗，有望为转移性肾细胞癌和转移性黑色素瘤患者带来持久缓解。高剂量白细胞介素-2 治疗引起的毒性作用影响所有器官系统，导致严重的急性发病率。由于与其他形式的抗癌治疗相比，毒性的严重程度和独特性，高剂量白细胞介素-2 治疗需要专业的护理和知识。然而，通过 vigilant monitoring 和适当的支持性护理方案，高剂量白细胞介素-2 治疗的毒性是可预测和可管理的。为了获得最佳结果，急性和延迟毒性都需要 vigilant monitoring 和熟练的症状管理。本综述详细介绍了接受高剂量白细胞介素-2 治疗的患者的病理生理学、监测参数和管理策略，重点介绍了新的和重要的管理原则。
